{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:44:29Z","timestamp":1791827069432,"version":"4.3.4"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.esmorw.2026.100805","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:44:30Z","timestamp":1791823470000},"page":"100805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond pairwise comparisons of androgen receptor signaling inhibitors in nonmetastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"S.","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2026.100805_bib1","article-title":"Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study","volume":"13","author":"Ishimoto","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100805_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102546","article-title":"Real-world effectiveness and treatment persistence of darolutamide, apalutamide, and enzalutamide in non-metastatic castration-resistant prostate cancer: a multicenter study","volume":"24","author":"Hara","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmorw.2026.100805_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:44:45Z","timestamp":1791823485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":3,"alternative-id":["S2949820126001244"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100805","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond pairwise comparisons of androgen receptor signaling inhibitors in nonmetastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100805"}}